Catalyst Biosciences Profit Margin

Catalyst Biosciences (CBIO) currently reports a profit margin of 421.62% as of June 2026. That compares with 13.75% in the prior-year period — up 2966.8% year over year. That is above the Healthcare sector average of 13.76%. Use the charts on this page to explore Catalyst Biosciences's profit margin history and peer comparisons.

Catalyst Biosciences's profit margin increased from 13.75% to 421.62% — a 2966.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Catalyst Biosciences's profit margin of 421.62% is higher than the Healthcare sector average of 13.76%. That is roughly 2964.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Catalyst Biosciences's current 421.62% should be judged against Healthcare norms (sector average: 13.76%) and against CBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 421.62%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Catalyst Biosciences, and consider following CBIO for alerts when major investors trade the stock.